Efficacy and safety of 5-aminolevulinic acid–guided surgery versus white-light resection in newly diagnosed glioblastoma: a systematic review and meta-analysis
Authors:
- 24 July 2026
- journal article
- review article
- Published by Springer Nature in Neurosurgical Review
- Vol. 49 (1) , 492
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Brain Tumor Networks in Diffuse GliomaNeurotherapeutics, 2022
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsBMJ, 2021
- Fluorescence guided resection and glioblastoma in 2015: A reviewLasers in Surgery and Medicine, 2015
- The Value of Extent of Resection of Glioblastomas: Clinical Evidence and Current ApproachCurrent Neurology and Neuroscience Reports, 2014
- Impact of fluorescence-guided surgery on the improvement of clinical outcomes in glioblastoma patientsNeuro-Oncology Practice, 2014
- Extent of resection influences outcomes for patients with gliomasRevue Neurologique, 2011
- Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trialThe Lancet Oncology, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Systems for grading the quality of evidence and the strength of recommendations I: Critical appraisal of existing approaches The GRADE Working GroupBMC Health Services Research, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003